Home > Oncology > ASCO 2020 > Genitourinary Cancer > Final survival results from phase 3 SPARTAN trial

Final survival results from phase 3 SPARTAN trial

Prof. Eric J. Small, University of California San Francisco, CA, USA
ASCO 2020
Phase 3, SPARTAN
Featured video: Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). In the phase 3 SPARTAN trial, the addition of apalutamide to androgen-deprivation therapy (ADT) improved median metastasis-free survival (MFS) and progression-free survival (PFS) in non-metastatic castration-resistant prostate cancer (nmCRPC), compared with placebo [1]. Now, overall survival data are mature, and this was also significantly improved in patients treated with apalutamide. ADT is the mainstay of treatment for metastatic prostate cancer. ADT is also an important part of care for many men with non-metastatic prostate cancer. However, although ADT is initially effective, castration-resistant disease eventually develops in almost all men with prostate cancer. The phase 3 SPARTAN trial eva...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on